Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos Therapeutics (PTHS – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Beam Therapeutics (BEAM)
In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Beam Therapeutics. The company’s shares closed last Monday at $25.94.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beam Therapeutics with a $48.91 average price target, implying a 90.4% upside from current levels. In a report issued on March 4, Evercore ISI also maintained a Buy rating on the stock with a $35.00 price target.
See the top stocks recommended by analysts >>
Pelthos Therapeutics (PTHS)
Alliance Global Partners analyst James Molloy reiterated a Buy rating on Pelthos Therapeutics today and set a price target of $75.00. The company’s shares closed last Monday at $23.05.
According to TipRanks.com, Molloy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pelthos Therapeutics with a $58.00 average price target, implying a 151.6% upside from current levels. In a report issued on March 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.
Vertex Pharmaceuticals (VRTX)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals today. The company’s shares closed last Monday at $473.73.
According to TipRanks.com, Ahmad is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $555.00 average price target, which is a 15.2% upside from current levels. In a report issued on March 10, Jefferies also initiated coverage with a Buy rating on the stock with a $580.00 price target.
